TP53 and acute myeloid leukemia: Altogether, these data confirm our above-described results from in vitro co-culture experiments corroborating our finding that the TP53 mutational status is a critical tumor-intrinsic genetic determinant of CAR T-cell therapeutic efficacy in AML in vitro and in vivo.